Virbac SA (VIRP.PA) — Quality & forensics
As of 2026-10-06 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 63
- Quality 54
- Growth 34
- Balance sheet 62
- Cash quality 48
- Capital allocation 36
- Momentum 31
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the VIRP.PA chart & overview
FAQ · from the current data · as of 2026-10-06
Quick answers
What is Virbac SA's Closelooknet quality reading?
The composite reads 48/100 across 7 modules, as of 2026-10-06: valuation 63, quality 54, growth 34, balance sheet 62, cash quality 48, capital allocation 36, momentum 31. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Virbac SA's Altman Z-Score?
3.37, which sits in the safe zone (above 2.99) as of 2026-10-06. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Virbac SA's Piotroski F-Score?
7 of 9, as of 2026-10-06. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Virbac SA's Beneish M-Score indicate?
-2.04 — below the −1.78 manipulation-risk threshold, as of 2026-10-06. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- LLY Eli Lilly and Companyindustry
- ORNAV.HE Orion Oyj Aindustry
- ORNBV.HE Orion Oyj Bindustry
- AMGN Amgen Incindustry
- NVO Novo Nordisk A/Sindustry
- ABBV AbbVie Incindustry
- BIIB Biogen Incindustry
- GILD Gilead Sciences Incindustry
- OGN Organon & Coindustry
- GRF.MC Grifols S.A.industry
- PFE Pfizer Incindustry
- MRK Merck & Company Incindustry
- JNJ Johnson & Johnsonindustry
- BMY Bristol-Myers Squibb Companyindustry
- SAN.PA Sanofi SAindustry
- GSK GlaxoSmithKline PLC ADRindustry
- SNY Sanofi ADRindustry
- AZN AstraZeneca PLCindustry
- EL.PA EssilorLuxottica S. A.sector
- ABVX.PA Abivax SAsector